Cargando…
Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of t...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246889/ https://www.ncbi.nlm.nih.gov/pubmed/32813887 http://dx.doi.org/10.1111/all.14565 |
_version_ | 1783716405526396928 |
---|---|
author | Barker‐Tejeda, Tomas Clive Bazire, Raphaelle Obeso, David Mera‐Berriatua, Leticia Rosace, Domenico Vazquez‐Cortes, Sonia Ramos, Tania Rico, Maria del Pilar Chivato, Tomás Barbas, Coral Villaseñor, Alma Escribese, Maria M. Fernández‐Rivas, Montserrat Blanco, Carlos Barber, Domingo |
author_facet | Barker‐Tejeda, Tomas Clive Bazire, Raphaelle Obeso, David Mera‐Berriatua, Leticia Rosace, Domenico Vazquez‐Cortes, Sonia Ramos, Tania Rico, Maria del Pilar Chivato, Tomás Barbas, Coral Villaseñor, Alma Escribese, Maria M. Fernández‐Rivas, Montserrat Blanco, Carlos Barber, Domingo |
author_sort | Barker‐Tejeda, Tomas Clive |
collection | PubMed |
description | BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono‐ or Poly‐sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects. METHODS: 47 grass‐pollen‐allergic patients were enrolled in a double‐blind, placebo‐controlled, multicenter trial using GRAZAX® during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono‐ or Poly‐sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly). RESULTS: Kinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly‐sensitized patients presented a higher inflammation at inclusion, while Mono‐sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment. CONCLUSIONS: The most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono‐sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point. |
format | Online Article Text |
id | pubmed-8246889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82468892021-07-02 Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics Barker‐Tejeda, Tomas Clive Bazire, Raphaelle Obeso, David Mera‐Berriatua, Leticia Rosace, Domenico Vazquez‐Cortes, Sonia Ramos, Tania Rico, Maria del Pilar Chivato, Tomás Barbas, Coral Villaseñor, Alma Escribese, Maria M. Fernández‐Rivas, Montserrat Blanco, Carlos Barber, Domingo Allergy ORIGINAL ARTICLES BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono‐ or Poly‐sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects. METHODS: 47 grass‐pollen‐allergic patients were enrolled in a double‐blind, placebo‐controlled, multicenter trial using GRAZAX® during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono‐ or Poly‐sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly). RESULTS: Kinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly‐sensitized patients presented a higher inflammation at inclusion, while Mono‐sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment. CONCLUSIONS: The most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono‐sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point. John Wiley and Sons Inc. 2020-09-22 2021-04 /pmc/articles/PMC8246889/ /pubmed/32813887 http://dx.doi.org/10.1111/all.14565 Text en © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Barker‐Tejeda, Tomas Clive Bazire, Raphaelle Obeso, David Mera‐Berriatua, Leticia Rosace, Domenico Vazquez‐Cortes, Sonia Ramos, Tania Rico, Maria del Pilar Chivato, Tomás Barbas, Coral Villaseñor, Alma Escribese, Maria M. Fernández‐Rivas, Montserrat Blanco, Carlos Barber, Domingo Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title | Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title_full | Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title_fullStr | Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title_full_unstemmed | Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title_short | Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
title_sort | exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246889/ https://www.ncbi.nlm.nih.gov/pubmed/32813887 http://dx.doi.org/10.1111/all.14565 |
work_keys_str_mv | AT barkertejedatomasclive exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT bazireraphaelle exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT obesodavid exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT meraberriatualeticia exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT rosacedomenico exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT vazquezcortessonia exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT ramostania exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT ricomariadelpilar exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT chivatotomas exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT barbascoral exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT villasenoralma exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT escribesemariam exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT fernandezrivasmontserrat exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT blancocarlos exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics AT barberdomingo exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics |